STTK
NASDAQ HealthcareShattuck Labs, Inc. - Common Stock
Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
�� 市场数据
| 价格 | $6.14 |
|---|---|
| 成交量 | 223,370 |
| 市值 | 622.25M |
| 贝塔系数 | 1.100 |
| RSI（14日） | 31.6 |
| 200日均线 | $5.72 |
| 50日均线 | $6.99 |
| 52周最高 | $8.33 |
| 52周最低 | $1.70 |
| Forward P/E | -11.82 |
| Price / Book | 2.96 |
🎯 投资策略评分
STTK 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (64/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 STTK in your text
粘贴任何文章、记录或帖子 — 工具将提取 STTK 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-24.